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Stroke is the leading cause of disability in the world
population Citicoline is an exogenous form of cytidine 5'-
diphosphatecholine, an important component of the
cellular membrane, is a medication believed to have
combined neurovascular protection and repair effects. It
is extensively studied in many clinical trials in patients
including ischaemic stroke however promising results on
meaningful clinical recovery and reduction of disability is
lacking. 
What was the trial? 
ICTUS trial was an international randomized multicentre
placebo-controlled trial to confirm the results of pooled
data in a large clinical trial available on the effect of
Citicoline on the recovery of patients with moderate to
severe acute ischaemic stroke at 3 months.
Who were patients and what was the
intervention? 
A total of 2298 patients from centers in Europe were
recruited during a period of six years. Patients had
moderate to severe anterior circulation stroke categorized
by the use of 3 scales (NIHSS, modified Rankin score,
Barthel index) for neurological impairment & functional
disability along with the physical examination&
radiological evidence. Patients were randomly assigned to
two groups. Treatment group was given 2000mg/day of
Citicoline initially intravenous then oral for a total of 6
weeks, in a double blinded fashion. rt-PA was used if
required in both groups. Both groups were comparable in
term of age, gender, time from stroke onset. 
What were the results? 
Primary outcome e.g. global recovery at 90 days was
similar in both groups with adjusted odds ratio for
primary outcome was 10.3(95% CI). Secondary objective
(rate of favourable response on single scale) showed no
difference with the treatment with citicoline. 
What were the conclusions? 
The author concluded that the trial failed to prove any
benefit of Citicoline treatment in the recovery from
ischaemic stroke in 90 days. Although previous
Metaanalysis showed some benefit of the treatment with
citicoline. 
Why is this important? 
Citicoline adds no clinical improvement to the patient's
clinical condition and is not a feasible choice for patients;
rather it increases the cost of care. In a resource poor
region these resources should be rationally utilized. 
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